Author: Li, Guangdi; Liu, Yacong; Jing, Xixi; Wang, Yali; Miao, Miao; Tao, Li; Zhou, Zhiguo; Xie, Yuanlin; Huang, Yaxiong; Lei, Jianhua; Gong, Guozhong; Jin, Ping; Hao, Yuantao; Faria, Nuno Rodrigues; Clercq, Erik De; Zhang, Min
Title: Mortality risk of COVID-19 in elderly males with comorbidities: a multi-country study Cord-id: 8wyzx398 Document date: 2020_12_31
ID: 8wyzx398
Snippet: The COVID-19 pandemic causes severe morbidity and mortality. This multi-country study aimed to explore risk factors that drive mortality in COVID-19 patients who received neither dexamethasone nor remdesivir. We analyzed a cohort of 568 survivors and 507 non-survivors from China, European regions, and North America. Elderly males ≥70 years accounted for only 25% of survivors, but this rate was significantly higher in non-survivors from China (55%), European regions (63%), and North America (47
Document: The COVID-19 pandemic causes severe morbidity and mortality. This multi-country study aimed to explore risk factors that drive mortality in COVID-19 patients who received neither dexamethasone nor remdesivir. We analyzed a cohort of 568 survivors and 507 non-survivors from China, European regions, and North America. Elderly males ≥70 years accounted for only 25% of survivors, but this rate was significantly higher in non-survivors from China (55%), European regions (63%), and North America (47%). Compared with survivors, non-survivors had more incidences of comorbidities such as cerebrovascular disease and chronic obstructive pulmonary disease (COPD, p-values<0.05). Survival analyses revealed age, male gender, shortness of breath, cerebrovascular disease, and COPD as mortality-associated factors. Survival time from symptom onset was significantly shorter in elderly versus young patients (median: 29 versus 62 days), males versus females (median: 46 versus 59 days), and patients with versus without comorbidities (mean: 41 versus 61 days). Mortality risk was higher in elderly males with comorbidities than in young females without comorbidities (p-value<0.01). Elderly male survivors with comorbidities also had longer hospital stays than other survivors (25 versus 18.5 days, p-value<0.01). Overall, the high mortality risk in elderly males with COVID-19-associated comorbidities supports early prevention and critical care for elderly populations.
Search related documents:
Co phrase search for related documents- accumulate evidence and additional information: 1
- acute cerebrovascular disease and liver disease: 1
- acute death respiratory distress syndrome and adaptive immune response: 1, 2
- acute death respiratory distress syndrome and adaptive innate: 1, 2, 3
- acute death respiratory distress syndrome and additional information: 1, 2
- acute death respiratory distress syndrome and lung cancer: 1, 2, 3
- acute respiratory distress syndrome and adaptive immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
- acute respiratory distress syndrome and adaptive innate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory distress syndrome and adaptive innate system: 1, 2, 3, 4, 5, 6, 7
- acute respiratory distress syndrome and additional information: 1, 2, 3, 4, 5
- acute respiratory distress syndrome and adequately reduce: 1
- acute respiratory distress syndrome and admission date: 1, 2, 3
- acute respiratory distress syndrome and liver disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory distress syndrome and long length: 1, 2
- acute respiratory distress syndrome and lung cancer: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- adaptive immune response and liver disease: 1
- adaptive immune response and lung cancer: 1
- adaptive innate and liver disease: 1, 2, 3, 4, 5, 6
- adaptive innate and lung cancer: 1, 2, 3, 4, 5, 6, 7
Co phrase search for related documents, hyperlinks ordered by date